Cyclosporin A in the treatment of refractory B chronic lymphocytic leukemia (B-CLL).
Partial tumoral responses have been described after cyclosporin A treatment in refractory B-chronic lymphocytic leukemia patients. We report the effect of this therapy in five patients prospectively treated with oral conventional dose of cyclosporin A. Antitumoral efficiency was marginal (one sustained partial response among five patients) which, added to a potential worsening of natural and therapy-related immunodepression, limits its use in this instance.
Van Den Neste
E
E
Département d'Hématologie de l'Université Catholique de Louvain, Brussels, Belgium.
Maerevoet
M
M
Martiat
P
P
Ferrant
A
A
Delannoy
A
A
Michaux
J L
JL
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000188:drug therapy*; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010976:Platelet Count / Q000187:drug effects
D000970:Antineoplastic Agents; D016572:Cyclosporine